Medwise Overseas Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Medwise Overseas Private Limited Pharmaceutical Export Portfolio Dataset — 19 Products, $4.4M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Medwise Overseas Private Limited — Pharmaceutical Exporter Profile (2026) | 19 Products, $4.4M Trade | TransData Nexus

Medwise Overseas Private Limited

Indian Pharmaceutical Exporter · Cardiovascular Specialist · $4.4M Total Trade · DGFT Verified

Medwise Overseas Private Limited is an Indian pharmaceutical exporter with a total trade value of $4.4M across 19 products in 10 therapeutic categories. Based on 161 verified export shipments from Indian Customs (DGFT) records, Medwise Overseas Private Limited is the #1 Indian exporter in 1 product including Morphine. Top exports include Rifampicin ($750.0K), Nifedipine ($646.9K), Immunoglobulin ($400.0K).

Medwise Overseas Private Limited — Export Portfolio & Destination Treemap

Medwise Overseas Private Limited pharmaceutical export portfolio — 19 products across 10 therapeutic categories. Source: Indian Customs (DGFT).

Who is Medwise Overseas Private Limited? — Company Overview & Market Position

Medwise Overseas Private Limited, established on August 17, 2015, is a private limited company headquartered in Daskroi, Gujarat, India. The company specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. With an authorized and paid-up capital of ₹5.10 million, Medwise operates as a non-government entity under the Corporate Identification Number (CIN) U21001GJ2015PTC084226.

As of March 2025, Medwise reported a total export value of $4.4 million USD, encompassing 161 shipments across 19 products in 10 therapeutic categories. The company's portfolio is notably concentrated, with the top five products accounting for 55% of total exports. The primary therapeutic categories include Cardiovascular (24.7%), Advanced Antibiotics (16.9%), and Advanced Oncology (16.5%).

What Does Medwise Overseas Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Rifampicin$750.0K 2Nifedipine

Product Portfolio — Top 19 by Export Value

Medwise Overseas Private Limited exports 19 pharmaceutical products across 10 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Rifampicin	Advanced Antibiotics	$750.0K	15	0.1%	9
2	Nifedipine	Cardiovascular	$646.9K	28	2.1%	11
3	Immunoglobulin	Other	$400.0K	8	0.2%	12
4	Isoniazid	Tuberculosis Medications	$356.8K	17	0.0%	13
5	Amiodarone	Cardiovascular	$281.2K	15	0.4%	12
6	Morphine	Analgesics & Antipyretics	$250.0K	5	1.4%	1
7	Rituximab	Advanced Oncology	$250.0K	5	1.3%	4
8	Everolimus	Immunosuppressants	$236.5K	5	0.6%	7
9	Etanercept	Biologics & Immunotherapy	$200.0K	4	0.3%	4
10	Trastuzumab	Advanced Oncology	$200.0K	4	0.3%	6
11	Fentanyl	Analgesics & Antipyretics	$164.6K	5	4.4%	6
12	Captopril	Cardiovascular	$163.7K	6	1.3%	7
13	Cyclosporine	Immunosuppressants	$114.7K	9	0.9%	13
14	Vincristine	Oncology	$111.5K	11	5.5%	3
15	Tamoxifen	Advanced Oncology	$85.0K	12	0.6%	9
16	Mitoxantrone	Advanced Oncology	$76.3K	3	4.0%	3
17	Cytarabine	Advanced Oncology	$70.4K	3	0.7%	12
18	Lapatinib	Advanced Oncology	$47.2K	3	0.9%	3
19	Sulfasalazine	Gastrointestinal	$22.3K	3	0.7%	11

Medwise Overseas Private Limited exports 19 pharmaceutical products across 10 therapeutic categories with a total export value of $4.4M. The company is the #1 Indian exporter in 1 product: Morphine. The top category is Cardiovascular (24.7% of portfolio), followed by Advanced Antibiotics (16.9%), reflecting a diversified portfolio where the top 5 products account for only 55.0% of total value.

Medwise Overseas Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Medwise operates multiple manufacturing facilities across India, each specializing in different pharmaceutical formulations. These facilities are equipped with state-of-the-art technologies and infrastructure, collectively spanning over 100,000 square feet. The company emphasizes compliance with international quality standards, ensuring that all products are manufactured at accredited sites in adherence to WHO Good Manufacturing Practices (GMP) norms.

3Key Leadership

The leadership team at Medwise comprises experienced professionals committed to the company's growth and innovation. Dr. Niral Patel, a Medical Doctor and Pharmacologist from B J Medical College, Ahmedabad, serves as the Promoter Director. His expertise in new product development and creation has been instrumental in the company's success. Dr. Kalpesh Jain, also a Medical Doctor and Pharmacologist from B J Medical College, Ahmedabad, holds the position of Promoter Director. His technical expertise, marketing insight, and visionary thinking have been pivotal in advancing Medwise to the next level.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Medwise Overseas Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Medwise has made significant strides in regulated markets, particularly in the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained various certifications, including WHO GMP and ISO 9001:2015, which are essential for market access in these regions. Medwise is actively seeking distribution partners in the USA, indicating a strategic focus on expanding its presence in developed markets.

2Emerging Markets

Medwise has established a presence in emerging markets across Africa, Latin America, and Southeast Asia. The company's adherence to WHO prequalification standards has facilitated access to these regions, enabling it to meet international quality benchmarks and expand its global footprint.

3Geographic Strategy

Medwise's geographic strategy demonstrates a balanced approach, with a strong presence in both developed and emerging markets. The company's focus on obtaining international certifications and seeking distribution partners in developed markets like the USA reflects a strategic direction aimed at diversification and reducing concentration risk. This approach positions Medwise to leverage growth opportunities across different regions.

Medwise Overseas Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Medwise has made significant progress in the U.S. market, obtaining FDA certifications for its products. The company is actively seeking distribution partners in the USA, indicating a strategic focus on expanding its presence in the U.S. market.

2WHO & EU GMP

Medwise ensures that all its products are manufactured at accredited sites in compliance with WHO GMP norms. The company has also achieved ISO 9001:2015 certification, reflecting its commitment to quality management systems.

3CDSCO & Indian Regulatory

Medwise holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and has obtained necessary approvals from state drug controllers. The company has also secured export No Objection Certificates (NOCs), facilitating its international trade operations.

4Recent Regulatory Actions

Medwise Overseas Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Medwise operates in a competitive landscape with several key players in the pharmaceutical export sector. While specific market share data is not publicly available, Medwise's focus on obtaining international certifications and seeking distribution partners in developed markets like the USA indicates a strategic approach to enhancing its competitive position.

2Key Differentiators

Medwise's key differentiators include its commitment to quality, timely delivery, cost-effectiveness, and post-sale support. The company's unique "Med-Advise" concept offers clients data provision, product suggestions, updated disease guidelines, research articles, weekly updates, and innovative packaging ideas, enhancing customer satisfaction and loyalty.

3Strategic Position

Medwise's current strategic direction focuses on expanding its presence in both developed and emerging markets. The company's pursuit of international certifications and distribution partnerships reflects a commitment to growth and market diversification. Looking ahead, Medwise aims to strengthen its position in the global pharmaceutical export sector by leveraging its strengths in quality manufacturing and customer-centric services.

Buyer Due Diligence Brief — Evaluating Medwise Overseas Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Medwise has demonstrated a strong track record in pharmaceutical manufacturing, with a diverse product portfolio and consistent export performance. The company's adherence to international quality standards and its proactive approach to market expansion indicate reliability and a commitment to excellence. Medwise's focus on customer satisfaction and post-sale support further underscores its dedication to building long-term, trustworthy relationships with clients.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Certification: Confirm that Medwise's products are FDA-approved for the U.S. market.

WHO GMP Certification: Ensure that manufacturing facilities comply with WHO Good Manufacturing Practices.

ISO 9001:2015 Certification: Verify the implementation of quality management systems.

Frequently Asked Questions — Medwise Overseas Private Limited

How many pharmaceutical products does Medwise Overseas Private Limited export from India?

Medwise Overseas Private Limited exports 19 pharmaceutical products across 10 therapeutic categories. The top exports are Rifampicin ($750.0K), Nifedipine ($646.9K), Immunoglobulin ($400.0K), Isoniazid ($356.8K), Amiodarone ($281.2K). Total export value is $4.4M.

What is Medwise Overseas Private Limited's total pharmaceutical export value?

Medwise Overseas Private Limited's total pharmaceutical export value is $4.4M, based on 161 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Medwise Overseas Private Limited the #1 Indian exporter?

Medwise Overseas Private Limited is the #1 Indian exporter in 1 products: Morphine (1.4% market share).

What therapeutic categories does Medwise Overseas Private Limited cover?

Medwise Overseas Private Limited exports across 10 therapeutic categories. The largest are Cardiovascular (24.7%, 3 products), Advanced Antibiotics (16.9%, 1 products), Advanced Oncology (16.5%, 6 products).

Get Full Medwise Overseas Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.